Trial watch: Dendritic cell (DC)-based immunotherapy for cancer DOI Creative Commons
Raquel S. Laureano, Jenny Sprooten,

Isaure Vanmeerbeerk

et al.

OncoImmunology, Journal Year: 2022, Volume and Issue: 11(1)

Published: July 4, 2022

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to paradigm-shifts immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed tumor-associated or -specific antigens (TAAs TSAs), the presence immunostimulatory molecules induce maturation, followed reinfusion into patients. Accordingly, can TAA/TSA-specific CD8+/CD4+ responses. Yet, still shows suboptimal anti-tumor efficacy clinic. Extensive efforts ongoing improve immunogenicity and vaccines, often employing combinatorial chemo-immunotherapy regimens. In Trial Watch, we summarize preclinical clinical developments discuss trends future perspectives DC-based immunotherapy oncological indications.

Language: Английский

Dendritic cells in cancer immunology and immunotherapy DOI
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal

et al.

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 20(1), P. 7 - 24

Published: Aug. 29, 2019

Language: Английский

Citations

1978
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer DOI Creative Commons
Lei Zhang, Ziyi Li,

Katarzyna M. Skrzypczynska

et al.

Cell, Journal Year: 2020, Volume and Issue: 181(2), P. 442 - 459.e29

Published: April 1, 2020

Language: Английский

Citations

1102
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion DOI
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre

et al.

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(5), P. 298 - 312

Published: March 9, 2021

Language: Английский

Citations

975
Endoplasmic reticulum stress signals in the tumour and its microenvironment DOI
Xi Chen, Juan R. Cubillos‐Ruiz

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 21(2), P. 71 - 88

Published: Nov. 19, 2020

Language: Английский

Citations

867
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment DOI Creative Commons
Heidi Harjunpää, Marc Llort Asens, Carla Guenther

et al.

Frontiers in Immunology, Journal Year: 2019, Volume and Issue: 10

Published: May 22, 2019

The immune system and cancer have a complex relationship with the playing dual role in tumor development. effector cells of can recognize kill malignant while system-mediated inflammation also promote growth regulatory suppress anti-tumor responses. In center all responses is ability to migrate site interact each other cells. Cell adhesion molecules including receptors immunoglobulin superfamily integrins are crucial importance mediating these processes. Particularly play vital regulating aspects cell function trafficking into tissues, activation proliferation formation immunological synapse between or target both during homeostasis cancer. this review we discuss molecular mechanisms integrin microenvironment. We describe how utilize metastases could be targeted immunotherapy.

Language: Английский

Citations

616
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies DOI
Tobias Bald, Matthew F. Krummel, Mark J. Smyth

et al.

Nature Immunology, Journal Year: 2020, Volume and Issue: 21(8), P. 835 - 847

Published: July 20, 2020

Language: Английский

Citations

371
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review DOI Open Access
Kyoko Oura, Asahiro Morishita, Joji Tani

et al.

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(11), P. 5801 - 5801

Published: May 28, 2021

Liver cancer has the fourth highest mortality rate of all cancers worldwide, with hepatocellular carcinoma (HCC) being most prevalent subtype. Despite great advances in systemic therapy, such as molecular-targeted agents, HCC one worst prognoses due to drug resistance and frequent recurrence metastasis. Recently, new therapeutic strategies immunosuppressive therapy have prolonged patients’ lives, combination an immune checkpoint inhibitor (ICI) VEGF is now positioned first-line for advanced HCC. Since efficacy ICIs depends on tumor microenvironment, it necessary elucidate environment select appropriate ICIs. In this review, we summarize findings microenvironment approaches focused monoclonal antibodies against cytotoxic T lymphocyte-associated protein 4 programmed cell death 1 We also describe ongoing treatment modalities, including adoptive transfer-based therapies future areas exploration based recent literature. The results pre-clinical studies using immunological classification animal models will contribute development biomarkers that predict aid selection treatment.

Language: Английский

Citations

313
Dendritic cell subsets in cancer immunity and tumor antigen sensing DOI Creative Commons
Annalisa Del Prete, Valentina Salvi, Alessandra Soriani

et al.

Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 20(5), P. 432 - 447

Published: March 22, 2023

Abstract Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles in both innate adaptive immune responses. Due to their ability cross-present tumor cell-associated antigens naïve T cells, DCs are instrumental the generation of specific T-cell-mediated antitumor effector responses control growth cell dissemination. Within an immunosuppressive microenvironment, DC functions can, however, be severely impaired. In this review, we focus on mechanisms capture activation by role microenvironment shaping functions, taking advantage recent studies showing phenotype acquisition, transcriptional state functional programs revealed scRNA-seq analysis. The therapeutic potential DC-mediated antigen sensing priming immunity is also discussed.

Language: Английский

Citations

266
Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity DOI

Jacqueline A. Carozza,

Volker Böhnert, Khanh Cong Nguyen

et al.

Nature Cancer, Journal Year: 2020, Volume and Issue: 1(2), P. 184 - 196

Published: Feb. 24, 2020

Language: Английский

Citations

260
Immunotherapy: Reshape the Tumor Immune Microenvironment DOI Creative Commons

Bingzhe LV,

Yunpeng Wang,

Dongjiang Ma

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: July 6, 2022

Tumor immune microenvironment (TIME) include tumor cells, cytokines, etc. The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of immunity. Although system can eliminate through cancer-immune cycle, tumors appear to eventually evade from surveillance by shaping an immunosuppressive microenvironment. Immunotherapy reshapes TIME restores killing ability cells. Herein, we review function cells within discuss contribution current mainstream immunotherapeutic approaches remolding TIME. Changes in different forms under intervention immunotherapy shed light on better combination treatment strategies.

Language: Английский

Citations

258